Novolog (Pharm-Up 1966) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Novolog (Pharm-Up 1966) şirketinin toplam hissedar öz sermayesi ₪393.1M ve toplam borcu ₪0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₪3.2B ve ₪2.8B dir. Novolog (Pharm-Up 1966) 'in FAVÖK'ü ₪69.1M faiz karşılama oranı 4.4 dur. Şirketin ₪239.9M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

₪0

Borç

Faiz karşılama oranı	4.4x
Nakit	₪239.95m
Eşitlik	₪393.14m
Toplam yükümlülükler	₪2.77b
Toplam varlıklar	₪3.16b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Nov 05

Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

Jul 25

I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

May 07

Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Apr 14

Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Mar 24

Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 09

How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

Feb 15

Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

Jan 25

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

Dec 29

With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

Dec 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NVLG 'nin kısa vadeli varlıkları ( ₪2.5B ) kısa vadeli yükümlülüklerini ( ₪2.6B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: NVLG şirketinin kısa vadeli varlıkları ( ₪2.5B ) uzun vadeli yükümlülüklerini ( ₪194.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NVLG borçsuzdur.

Borcun Azaltılması: NVLG şirketinin 5 yıl önce borç/öz sermaye oranı 0.2% iken borcu yok.

Borç Kapsamı: NVLG un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: NVLG şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Novolog (Pharm-Up 1966) Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Upcoming dividend of ₪0.02 per share

Third quarter 2024 earnings released: EPS: ₪0.023 (vs ₪0.001 in 3Q 2023)

Now 20% overvalued after recent price rise

Novolog (Pharm-Up 1966) Ltd to Report Q3, 2024 Results on Nov 20, 2024

Upcoming dividend of ₪0.029 per share

Second quarter 2024 earnings released: EPS: ₪0.026 (vs ₪0.023 in 2Q 2023)

Novolog (Pharm-Up 1966) Ltd to Report Q2, 2024 Results on Sep 04, 2024

Novolog (Pharm-Up 1966) Ltd, Annual General Meeting, Aug 05, 2024

First quarter 2024 earnings released: EPS: ₪0.024 (vs ₪0.02 loss in 1Q 2023)

Novolog (Pharm-Up 1966) Ltd to Report Q1, 2024 Results on May 21, 2024

Full year 2023 earnings released: ₪0.082 loss per share (vs ₪0.094 profit in FY 2022)

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: ₪0.001 (vs ₪0.02 in 3Q 2022)

Estimating The Fair Value Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG)

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: ₪0.023 (vs ₪0.024 in 2Q 2022)

Be Wary Of Novolog (Pharm-Up 1966) (TLV:NVLG) And Its Returns On Capital

First quarter 2023 earnings released: ₪0.02 loss per share (vs ₪0.024 profit in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: ₪0.094 (vs ₪0.084 in FY 2021)

Investor sentiment deteriorates as stock falls 17%

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2022 Results on Mar 20, 2023

Investor sentiment deteriorates as stock falls 15%

Novolog (Pharm-Up 1966) Ltd Appoints Tami Gottlieb as an Independent Non-Executive Director

Third quarter 2022 earnings released: EPS: ₪0.02 (vs ₪0.02 in 3Q 2021)

Insufficient new directors

Novolog (Pharm-Up 1966) Ltd to Report Q3, 2022 Results on Nov 16, 2022

Second quarter 2022 earnings released: EPS: ₪0.024 (vs ₪0.02 in 2Q 2021)

Insufficient new directors

Novolog (Pharm-Up 1966) Ltd to Report Q2, 2022 Results on Aug 10, 2022

Insufficient new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Novolog (Pharm-Up 1966) Ltd to Report Q1, 2022 Results on May 18, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Novolog (Pharm-Up 1966) Ltd to Report Q4, 2021 Results on Mar 14, 2022

Third quarter 2021 earnings released: EPS ₪0.022 (vs ₪0.021 in 3Q 2020)

I Ran A Stock Scan For Earnings Growth And Novolog (Pharm-Up 1966) (TLV:NVLG) Passed With Ease

Read This Before Buying Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) For Its Dividend

Novolog (Pharm-Up 1966)'s (TLV:NVLG) Earnings Are Of Questionable Quality

Upcoming dividend of ₪0.032 per share

Full year 2020 earnings released: EPS ₪0.086 (vs ₪0.026 in FY 2019)

Novolog (Pharm-Up 1966) Ltd to Report Fiscal Year 2020 Results on Mar 17, 2021

Novolog (Pharm-Up 1966) Ltd's (TLV:NVLG) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

How Much Of Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) Do Insiders Own?

New 90-day low: ₪2.76

Update: Novolog (Pharm-Up 1966) (TLV:NVLG) Stock Gained 88% In The Last Three Years

Novolog (Pharm-Up 1966) Ltd announced that it has received ILS 119.999999 million in funding

How Much Is Novolog (Pharm-Up 1966) Ltd (TLV:NVLG) CEO Getting Paid?

With EPS Growth And More, Novolog (Pharm-Up 1966) (TLV:NVLG) Is Interesting

Third quarter 2020 earnings released: EPS ₪0.021

Market bids up stock over the past week

New 90-day high: ₪3.20

New 90-day high - ₪3.09

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin